Mylan Blasts Apotex Challenge To Generic Benicar Exclusivity

Law360, Washington (April 10, 2013, 5:09 PM EDT) -- Mylan Pharmaceuticals Inc. Tuesday blasted Apotex Inc.'s attempt to strip it of its exclusive rights to market a generic version of Daiichi Sankyo Co. Ltd.'s hypertension drug Benicar, urging an Illinois federal judge to toss the case because Apotex's quest is impossible.

Mylan alleged in its motion to dismiss that Apotex “sat on its hands” while Mylan gained 180 days of generic exclusivity rights after it filed a paragraph IV certification challenging two Daiichi patents covering various doses of olmesartan medoxomil, the generic name of Benicar,...
To view the full article, register now.